Genetic deletion, pharmacological inhibition of the SHH-HSP90β axis, or delivery of miR-28-5p to macrophages in the male mice liver, impairs NASH symptomatic development. The gene discussed is HSP90AB1; the disease is metabolic dysfunction-associated steatohepatitis.